Patents by Inventor William T. Bradner

William T. Bradner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Rigolettone antitumor complex
    Patent number: 4792522
    Abstract: A novel complex designated herein as rigolettone complex is produced by fermentation of Streptomyces aburaviensis strain C-38,242 (ATCC 39290). The complex and its purified bioactive components, jildamycin and mantuamycin, exhibit antitumor activity in mouse tumor systems.
    Type: Grant
    Filed: August 22, 1985
    Date of Patent: December 20, 1988
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., Stanley W. Bray, James A. Bush, William T. Bradner
  • Process for producing rebeccamycin
    Patent number: 4552842
    Abstract: A novel antitumor agent designated herein as rebeccamycin is produced by fermentation of Nocardia aerocolonigenes (ATCC 39243). Rebeccamycin and its 5'-N-methyl and 5',2",3",6"-tetraacetate derivatives exhibit activity against experimental animal tumor systems.
    Type: Grant
    Filed: April 13, 1984
    Date of Patent: November 12, 1985
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner, Terrence W. Doyle
  • Rebeccamycin and process for its preparation
    Patent number: 4487925
    Abstract: A novel antitumor agent designated herein as rebeccamycin is produced by fermentation of Nocardia aerocolonigenes (ATCC 39243). Rebeccamycin and its 5'-N-methyl and 5',2",3",6"-tetraacetate derivatives exhibit activity against experimental animal tumor systems.
    Type: Grant
    Filed: January 28, 1983
    Date of Patent: December 11, 1984
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner, Terrence W. Doyle
  • Fermentation process for making rachelmycin
    Patent number: 4301248
    Abstract: A known antibiotic substance designated herein as rachelmycin is produced by fermentation of Streptomyces sp. strain C-329, variant 70 (ATCC 31128) or Streptomyces anandii subsp. arraffinosus strain C-22, 437 (ATCC 31431). Rachelmycin exhibits both antibiotic and antitumor properties.
    Type: Grant
    Filed: October 6, 1980
    Date of Patent: November 17, 1981
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner
  • Antibiotic complex producing bacterial culture
    Patent number: 4248970
    Abstract: A novel anthracycline antibiotic complex designated herein as figaroic acid complex is produced by fermentation of Streptosporangium sp. strain C-31,751, A.T.C.C. 31129. Figaroic acid complex inhibits the growth of various microorganisms, e.g., Staphylococcus aureus, exhibits phage inducing properties and inhibits the growth of various tumors in rodents, e.g., Sarcoma 180, L-1210 lymphatic leukemia, B-16 melanoma, Walker 256 carcinosarcoma and P-388 lymphatic leukemia.
    Type: Grant
    Filed: May 30, 1978
    Date of Patent: February 3, 1981
    Assignee: Bristol-Myers Company
    Inventors: William T. Bradner, James A. Bush, Donald E. Nettleton, Jr.
  • Antibiotic compound
    Patent number: 4162938
    Abstract: A novel anthracycline antibiotic designated rudolphomycin is produced by fermentaion of Actinosporangium sp. ATCC 31127 and isolation of the new antibiotic free of substances co-produced therewith. Rudolphomycin and its pharmaceutically acceptable salts exhibit antimicrobial activity and inhibit the growth of mammalian tumors.
    Type: Grant
    Filed: May 30, 1978
    Date of Patent: July 31, 1979
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., Terrence W. Doyle, William T. Bradner
  • Antibiotic compound
    Patent number: 4123608
    Abstract: A novel anthracycline antibiotic designated rudolphomycin is produced by fermentation of Actinosporangium sp. ATCC 31127 and isolation of the new antibiotic free of substances co-produced therewith. Rudolphomycin and its pharmaceutically acceptable salts exhibit antimicrobial activity and inhibit the growth of mammalian tumors.
    Type: Grant
    Filed: January 25, 1978
    Date of Patent: October 31, 1978
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., Terrence W. Doyle, William T. Bradner
  • Antibiotic complex
    Patent number: 4112071
    Abstract: A novel anthracycline antibiotic complex designated herein as figaroic acid complex is produced by fermentation of Streptosporangium sp. strain C-31,751, A.T.C.C. 31129. Figaroic acid complex inhibits the growth of various microorganisms, e.g., Staphylococcus aureus, exhibits phage inducing properties and inhibits the growth of various tumors in rodents, e.g., Sarcoma 180, L-1210 lymphatic leukemia, B-16 melanoma, Walker 256 carcinosarcoma and P-388 lymphatic leukemia.
    Type: Grant
    Filed: September 9, 1977
    Date of Patent: September 5, 1978
    Assignee: Bristol-Myers Company
    Inventors: William T. Bradner, James A. Bush, Donald E. Nettleton, Jr.
  • Antibiotic compounds marcellomycin and musettamycin
    Patent number: 4064014
    Abstract: A novel anthracycline antibiotic complex designated herein as bohemic acid complex is produced by fermentation of Actinosporangium sp. A.T.C.C. 31127. The complex and two bioactive components designated marcellomycin and musettamycin exhibit antibiotic activity and inhibit the growth of various tumor systems in rodents.
    Type: Grant
    Filed: March 23, 1977
    Date of Patent: December 20, 1977
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner, Richard H. Schreiber
  • Antibiotic compounds marcellomycin and musettamycin
    Patent number: 4039736
    Abstract: A novel anthracycline antibiotic complex designated herein as bohemic acid complex is produced by fermentation of Actinosporangium sp. A.T.C.C. 31127. The complex and two bioactive components designated marcellomycin and musettamycin exhibit antibiotic activity and inhibit the growth of various tumor systems in rodents.
    Type: Grant
    Filed: April 15, 1976
    Date of Patent: August 2, 1977
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner, Richard H. Schreiber